EFFECT OF CARBAZILQUINONE ON LYMPHOID LEUKEMIA L-1210

ARAKAWA Masao, AOKI Takuzo, NAKAO Hideo

doi:10.20772/cancersci1959.61.5_485

Carbazilquinone, 2, 5-bis(1-aziridinyl)-3-(2-carbamoyloxy-1-methoxyethyl)-6-methyl-1, 4-benzoquinone, was tested for antitumor activity against lymphoid leukemia L-1210 in BDF₁ mice. The compound was remarkably effective against L-1210 following continued, intermittent, or single intraperitoneal administration. Effectiveness of the compound was compared with Methotrexate, Mitomycin-C, Cytoxan, and Trenimon following single and continued intraperitoneal administration which started 24hr after the intraperitoneal inoculation of L-1210 cells. It was found that both therapeutic ratio and maximum effectiveness of Carbazilquinone were the highest of those of other agents tested.<br>The compound also prolonged the life-span of the intravenously inoculated leukemic mice even in a terminal condition. The life-span of the treated mice was 13.5 days from the start of the treatment as compared to 1.5 days in control mice when the drug was given intravenously to the mice 5 days after intravenous inoculation of L-1210 cells. It was also effective on i.p.-i.v. system.<br>Further oral administration of the compound gave the leukemic mice more than two-fold increase in life-span over the untreated control mice.

EFFECT OF CARBAZILQUINONE ON LYMPHOID LEUKEMIA L-1210

Description

Journal

Details 詳細情報について

Export

Report a problem